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A comparison of the effects of perindopril arginine and amlodipine on choroidal
thickness in patients with primary hypertension
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Background/aim: This study aimed to investigate the effects of two different medical treatment options on choroidal thickness (CT) in
patients with primary hypertension.
Materials and methods: Forty newly diagnosed primary hypertension patients and 21 healthy volunteers were included. The patients
were randomly divided into two subgroups. Group I started on perindopril arginine and Group II started on amlodipine. Submacular
CT using optical coherence tomography (OCT) was measured before treatment and at the third and sixth months after treatment.
Results: Initial mean arterial pressure (MAP) values in Groups I and II and the control group were 113.4, 109.8, and 89.4 mmHg,
respectively, and mean CT values were 257.9, 286.5, and 300.9 µm. Mean MAP values in Groups I and II and the control group at the
sixth month after treatment were 99.7, 99.6, and 90.2 mmHg, respectively, and mean CT values were 293.1, 286, and 297.4 µm. Analysis
of the changes occurring during the study revealed significant variation in MAP in Groups I and II, and in CT in Group I only.
Conclusion: A gradual increase in CT developed with perindopril arginine therapy in patients with primary hypertension, while no
significant change occurred in CT in the amlodipine group.
Key words: Amlodipine, hypertension, perindopril, choroid, optical coherence tomography

1. Introduction
Hypertension, defined as systemic blood pressure
elevation, is a relatively common public health problem
capable of causing morbidity and mortality (1,2). It can
affect all organs and systems in the body. Patients with
preexisting hypertension are at greater risk of stroke,
myocardial infarction, heart failure, peripheral vascular
disease, kidney disease, and various potential ocular
complications, particularly in the retina and optic nerve
(3–5). Hypertension is therefore an important modifiable
risk factor in terms of treatment and of preventing such
complications (3).
In addition to the modification of predisposing
lifestyle habits, the treatment of hypertension may involve
such medical options as angiotensin converting enzyme
inhibitors (ACEIs), calcium channel blockers (CCBs), or
thiazide-type diuretic therapies (5).
ACEIs prevent the formation of angiotensin II, a
powerful vasoconstrictor, by inhibiting the enzyme
ACE that catalyzes the conversion of angiotensin I into
angiotensin II. This enzyme also breaks down bradykinin,

a vasodilator peptide. ACEIs thus cause an increase in
bradykinin levels. The end result is an antihypertensive
effect, as peripheral vascular resistance decreases
due to vasodilatation (6). Perindopril arginine is an
antihypertensive drug from this group (7).
CCBs reduce muscle tone by inhibiting voltagedependent calcium channels in the vascular smooth
muscle and myocardial cell membrane. This again leads
to an antihypertensive effect as peripheral vascular
resistance decreases due to vasodilatation. Amlodipine is
an antihypertensive drug from this group (8).
Approximately 95% of the blood flow entering the eye
passes into the uveal tissue, the vascular layer of the eye.
Approximately 70% of it reaches the choroidal segment
of the uvea (9). Choroidal circulation is largely controlled
by autonomic innervation (10). The main function of the
choroid, the tissue with the greatest blood flow per unit
weight, is to provide oxygen and metabolite support to the
outer part of the retina (11).
Choroidal tissue is implicated in ocular involvement in
various systemic diseases and in the development of several
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diseases of the eye. Advances in imaging technologies
have greatly facilitated the examination of the choroidal
structure, in turn illuminating the etiopathogenesis of
several diseases of choroidal origin. Optical coherence
tomography (OCT) is a noninvasive, repeatable, and
reproducible cross-sectional tissue-imaging modality
employed by ophthalmologists (12,13). Data elicited by
means of OCT, such as peripapillary retinal nerve fiber
layer thickness, ganglion cell complex, retinal thickness,
and choroidal thickness (CT), are of considerable
importance in the diagnosis and monitoring of numerous
ocular and systemic diseases (9,12–17).
Hypertension causes various changes in the
microvascular structure of the eye (4,18). Akay et al.
reported relatively lower CT values in hypertensive subjects
compared to a healthy control group (18). However, due
to the cross-sectional design of that study, changes in CT
occurring with the treatment of hypertension could not
be evaluated. The purpose of this study was to investigate
CT values in hypertensive patients and to evaluate the
probable effects on CT of two different therapeutic options
used in the treatment of hypertension.
2. Materials and methods
This prospective study was performed between August
2014 and May 2015 at the Karadeniz Technical University
Faculty of Medicine’s Department of Ophthalmology
in Trabzon, Turkey. Ethical committee approval was
received for the research. Forty newly diagnosed primary
hypertension patients presenting to the ophthalmology
clinic for hypertensive retinopathy check-up and 21 healthy
volunteers presenting for refractive error examination
were included in the study. Informed consent was received
from all participants.
Inclusion criteria for the hypertensive cases were age
over 18, hypertension being newly diagnosed, no previous
history of antihypertensive drug use, and no eye disease or
additional systemic disease capable of affecting blood flow
in the eye or CT, other than hypertension. Inclusion criteria
for the control group were age over 18 and having no eye
disease or additional systemic disease capable of affecting
blood flow in the eye or CT. Patients diagnosed with forms
of hypertension other than primary hypertension, with
a history of ocular surgery or trauma, with a spherical
equivalent of ±5 diopters, or with additional systemic
disease such as diabetes mellitus, heart disease, kidney
disease, thyroid disease, or any disease that may affect CT
were excluded.
All participants underwent basal arterial blood
pressure measurements and detailed eye examination.
Systemic blood pressure was measured from the right arm
in a quiet room after subjects had been allowed to rest in
chairs, using a sphygmomanometer. All measurements
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were performed by the same experienced nurse who was
blinded to the groups to which the subjects belonged, from
the same arm, allowing subjects time to rest, with subjects
in a seated position, and in the same time interval (1300–
1500 hours).
Eye examinations included best corrected visual acuity
measurement, anterior-posterior segment examinations
with the help of a biomicroscope, and intraocular pressure
(IOP) measurement. CT measurements were performed
using an OCT device (Optovue RTVue, RT100, software
version 6.3, Optovue Inc., Fremont, CA, USA). CT was
measured as previously described elsewhere (12,19).
Briefly, the scan protocol was established as a retina crossline consisting of two orthogonal 6-mm lines made up of
1024 A-scans. Subsequently, in order to elicit improved
visualization of the choroidal layer, the numbers of scans
were adjusted to 80 by selecting the chorioretinal scanning
mode on “Manual Tab” and the “Auto All” function
on “Auto Tab.” Choroidal imaging was carried out in
cross-line scanning mode. CT was measured from three
different levels: the fovea, 1000 µm nasal to the fovea, and
1000 µm temporal to the fovea, using the manual method,
by determining the region between the outer margin of
the retinal pigment epithelium and the inner margin of
the sclera (Figure 1). Mean values for these measurements
were subsequently calculated and adopted as the CT value
for the eye concerned. Measurements were performed by
the same author and in the same time interval (1300–1500
hours).
Hypertensive patients were randomly assigned to one
of two systemic therapy groups. Group I (n = 19) was
started on perindopril arginine (Coversyl 5 mg tablets, Les
Laboratoires Servier Industrie, Gidy, France) once a day
and Group II (n = 21) on amlodipine besylate (Norvasc 5
mg tablets, Pfizer Labs, New York, NY, USA) once a day.
Arterial blood pressure measurements and detailed ocular
examinations were performed three times as described in
all cases at the third and sixth months of follow-up.
Arterial blood pressure values measured at three
consecutive examinations in all three groups were
recalculated using the formula mean arterial pressure
(MAP) = diastolic blood pressure + (systolic blood

Figure 1. Choroidal thickness measured manually at OCT
imaging in one case.
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pressure – diastolic blood pressure) / 3. IOP and CT values
were calculated based on mean measurements for both
eyes.
2.1. Statistical analysis
Measurement data were expressed as mean ± standard
deviation and descriptive data as number and percentage.
All data were analyzed with SPSS 13.0.1 (SPSS Inc.,
Chicago, IL, USA). Nonparametric tests were employed
in statistical comparisons since the sample size was less
than 30 in all three groups. Friedman’s test was used to
compare consecutive dependent data measured in all
groups. Wilcoxon’s test was used in two-way comparisons
of measurement data identified as significant in the first
test. Comparisons between groups were performed using
the Kruskal–Wallis test. The Mann–Whitney U test with
Bonferroni correction was applied to data for which
significant variation was observed. The chi-square test was
used to compare descriptive data. P < 0.05 was regarded as
statistically significant.
3. Results
The mean ages of our subjects were 49.63 ± 7.98 years (33–
60) in Group I (n = 19), 48.76 ± 10.29 (23–60) in Group
II (n = 21), and 44.9 ± 7.29 (30–55) in the healthy control
group (n = 21). The differences between the three groups
were not statistically significant (P = 0.119). Eight (57.9%)
subjects in Group I were female and 8 (42.1%) were male.
In Group II, 13 (61.9%) subjects were female and 8 (38.1%)
were male, while in the control group, 14 (66.7%) subjects
were female and 7 (33.3%) were male. No statistically
significant difference was determined between the three
groups in terms of sex distribution (P = 0.848).
No significant difference was observed between
the hypertensive groups (I and II) in terms of baseline
MAP, IOP, and CT values (P = 0.054, P = 0.421, and P =
0.236, respectively). However, a significant difference was
determined between the hypertensive groups and the
control group in terms of baseline MAP values (for Group
I vs. the control group, P < 0.0001, and for Group II vs.
the control group, P < 0.0001). No significant difference
was determined in terms of basal IOP values (for Group
I vs. the control group, P = 0.915, and for Group II vs.
the control group, P = 0.449) and CT (for Group I vs. the
control group, P = 0.117, and for Group II vs. the control
group, P = 0.651).
We subsequently assessed whether any significant
difference was present among the groups in terms of third
month data. No significant difference was determined in
MAP, IOP, or CT values between the hypertensive groups
(Groups I and II) (P = 0.63, P = 0.036, and P = 0.592,
respectively). A significant difference was determined
between the hypertensive groups and the healthy control
group in terms of MAP values (P < 0.0001 for Group I vs.

the control group and P < 0.007 for Group II vs. the control
group). However, no significant difference was observed in
IOP (P = 0.668 for Group I vs. the control group, P = 0.71
for Group II vs. the control group) or CT (P = 0.537 for
Group I vs. the control group, P = 0.96 for Group II vs. the
control group) values.
There was no significant difference between the
hypertensive groups in terms of the sixth month data
(Groups I and II) in terms of MAP, IOP, or CT values (P =
0.748, P = 0.017, and P = 0.81, respectively). However, we
determined significant differences in MAP values between
the hypertensive groups and the healthy control group (P
< 0.0001 for Groups I and II vs. the control group). There
was no significant difference in terms of IOP (P = 0.592
for Group I vs. the control group, and P = 0.042 for Group
II vs. the control group) or CT (P = 0.957 for Group I vs.
the control group, and P = 0.88 for Group II vs. the control
group).
MAP values for the study groups obtained at the
three different study intervals are shown in Table 1.
While no significant difference was determined between
consecutive MAP values in the control group, MAP values
decreased significantly in Groups I and II (Figure 2).
This decrease in Group I was significant in the third and
sixth months compared to baseline (P < 0.0001 for both),
while the decrease in MAP values between the third and
sixth months was insignificant (P = 0.238). The decrease
in Group II was also significant in the third and sixth
months compared to baseline (P = 0.007 and P < 0.0001,
respectively), while the difference between the third and
sixth months was insignificant (P = 0.813).
IOP values in the groups from the three different
time intervals are shown in Table 2. Analysis revealed no
significant difference in consecutive IOP measurements in
the three groups (Figure 3).
CT values from the three time intervals are shown in
Table 3. While no significant difference was determined
between consecutive CT values in Group II or the control
group, a gradual increase in CT values was observed in
Group I (Figure 4). This increase in Group I was significant
at months 3 and 6 compared to baseline (P = 0.02 and P =
0.009, respectively), but the difference between months 3
and 6 was insignificant (P = 0.059).
The decreases in MAP obtained with medical treatment
at the sixth month compared to baseline in the hypertensive
groups were 11.49 ± 9.39 (1.67–26.67) mmHg in Group I
and 9.44 ± 14.35 (13.33–46.67) mmHg in Group II. There
was no significant difference between the two groups in
terms of decreases in MAP values (P = 0.668).
4. Discussion
Choroid tissue, the most richly vascularized area in the
entire body, provides nourishment and oxygenation for
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Table 1. MAP values at different time intervals in the study groups.
Mean arterial pressure (mmHg)

Groups

P-value

Baseline

3rd month

6th month

Group I

113.4 ± 6.8
(103.3–133.3)

101.9 ± 9.1
(83.3–121.7)

99.7 ± 7.8
(80–110)

<0.0001

Group II

109.8 ± 4.1
(105–120)

100.4 ± 12.8
(70–123.3)

99.6 ± 6.2
(90–111.3)

0.007

Control

89.4 ± 9
(70–100)

90.7 ± 7.9
(73.3–106.7)

90.2 ± 7.7
(71.7–100)

0.474

0.054
<0.0001
<0.0001

0.63
<0.0001
0.007

0.748
<0.0001
<0.0001

P-value
I vs. II
I vs. control
II vs. control

Figure 2. Changes in MAP values obtained at consecutive measurements in the study
groups.
Table 2. Mean IOP values at different time intervals in the study groups.

Groups

Mean intraocular pressure (mmHg)
3rd month

6th month

Group I

14.8 ± 2.4
(10.5–19)

15.6 ± 1.9
(12.5–18.5)

15.3 ± 2.2
(10.5–19)

0.521

Group II

14.2 ± 2.4
(10.5–20)

13.9 ± 3.4
(9.5–21.5)

13.6 ± 2.2
(11–19)

0.63

Control

15 ± 3
(9.5–21)

15.3 ± 2.8
(10.5–22.5)

15 ± 2.8
(8.5–21.5)

0.692

0.421
0.915
0.449

0.036
0.668
0.071

0.017
0.592
0.042

P-value
I vs. II
I vs. control
II vs. control

the outer layers of the retina, and is also responsible for
temperature regulation in the eye. Impacts on choroidal
blood flow can therefore lead to photoreceptor cell
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P-value

Baseline

dysfunction (20–22). Due to its role in the essential
functions of the eye, impairment of choroidal blood
flow plays a key role in the pathogenesis of various
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Figure 3. Changes in mean IOP values obtained at consecutive measurements in the
study groups.
Table 3. Mean CT values at different time intervals in the study groups.
Mean choroidal thickness (µm)

Groups

P-value

Baseline

3rd month

6th month

Group I

257.9 ± 85.8
(119.3–479.7)

279.8 ± 68.1
(167.7–459.5)

293.1 ± 68.6
(178.5–437.8)

0.003

Group II

286.5 ± 81.1
(140.2–475.2)

291.8 ± 88.7
(140.3–531.2)

286 ± 74.7
(141.3–411.5)

0.055

Control

300.9 ± 87.2
(152.8–559)

295.1 ± 82
(175.3–511.5)

297.4 ± 82.5
(166.3–532.8)

0.64

0.236
0.117
0.651

0.592
0.537
0.96

0.81
0.957
0.88

P-value
I vs. II
I vs. control
II vs. control

Figure 4. Changes in mean CT values obtained at consecutive measurements in the
study groups.

diseases, such as diabetic retinopathy, age-related macular
degeneration, and glaucoma (23). Various studies have
reported that the thickness of choroid tissue is affected

by various diseases, including high myopia and retinal
dystrophy, age-related macular degeneration, angioid
streak, polypoidal choroidal vasculopathy, central serous
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chorioretinopathy, and Vogt–Koyanagi–Harada disease
(24–29). Impacts on CT are thus implicated in various
pathologies. Since choroidal tissue has a dense vascular
structure, any pathological condition affecting the vessels
may compromise choroid health.
This study investigated changes in MAP, IOP, and
CT in patients with primary hypertension receiving
perindopril arginine, from the ACEI group, and
amlodipine, from the CCB group. Significant and similar
decreases in MAP were achieved with both perindopril
arginine and amlodipine therapies. Similarly, Zannad
et al. (30) compared the antihypertensive effects of
perindopril arginine and amlodipine and determined no
statistically significant difference in the peak effects of the
two drugs.
Analysis of the final CT measurements revealed
a statistically significant increase in CT levels in the
perindopril arginine group, but no significant change
in the amlodipine group. Drugs from the CCB group,
such as nifedipine and amlodipine, are dihydropyridine
derivatives that bind to smooth muscle cells with high
selectivity. Calcium levels in smooth muscle cells are partly
regulated by endothelin-1, which has vasoconstrictor
effects (31,32). Studies have shown that amlodipine
and nifedipine prevent vasoconstriction by affecting
endothelin-1 (33–35). ACE and renin-angiotensin system
components, which enable the conversion of angiotensin
I into angiotensin II, are also known to be present in
ocular tissue (36). In light of the pharmacological effect
mechanisms of the antihypertensive drugs used in the
study, it seems possible that perindopril arginine use is
also involved in an increase in CT with an additional
mechanism leading to a rise in bradykinin in tissues.
Similar decreases in MAP observed in the groups
using perindopril arginine and amlodipine in our
study suggest that changes in CT may be independent
of decreases in MAP. Zengin et al. (37) examined
CT changes emerging after 1 month of treatment in
hypertensive patients using a lisinopril dihydrate +
hydrochlorothiazide combination. They reported that the
decrease in blood pressure with antihypertensive therapy
did not affect CT. They also attributed this to the intense
sympathetic innervation and autoregulation mechanisms
in the choroid (37). In contrast to that study, we used
perindopril arginine, another drug from the ACEI group,
and observed a progressive increase in CT values in cases
using it. These differing results for CT changes in the two
studies may be due to Zengin et al.’s (37) follow-up period
being considerably shorter than our own, or due to the
drugs having different chemical contents and thus to
having exhibiting differing pharmacological effects.
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Various drugs used systemically may affect IOP
levels. Ganekal et al. (38) showed that the application
of CCB group drugs lowered IOP in rabbits. Although
the mechanism underlying this effect of CCB group
drugs is uncertain, it has been suggested that this may
occur by altering aqueous humor secretion by affecting
connections between pigmented and nonpigmented
ciliary epithelial cells or cation transfer in nonpigmented
ciliary cells (39,40). In contrast to Ganekal et al. (38),
Beatty et al. (41) stated that topical use of CCBs caused
an increase in IOP levels. Payne et al. (42) reported that
topical use of CCBs in rabbits had no effect on IOP, but
that systemic application caused a decrease in IOP levels.
Kelly et al. (43) reported that systemic use of the CCB
nifedipine had no significant effect on IOP. Another study
reported that topical application of enalaprilat, from the
ACEI group, led to a fall in IOP in monkeys (44). One
study involving healthy volunteers reported that oral use
of ACEI medications had no significant effect on IOP,
despite causing a significant decrease in blood pressure
(45). Two different drugs were used in our study, one
from the CCB group and one from the ACEI group, and
no significant change in IOP values was determined in
either group, despite a decrease in MAP values.
One study reported that a fall in IOP developing as a
result of the systemic application of 20% mannitol infusion
in glaucoma patients with asymmetric glaucoma resulted
in an increase in CT values (46). That study also observed
a greater increase in CT in eyes with a greater decrease
in IOP. The change in CT resulting from treatment in
the hypertensive groups in our study may therefore be
associated with changes in IOP. However, no significant
difference was observed between the perindopril arginine
and amlodipine groups in changes in IOP after treatment.
The statistically significantly greater increase in CT in
patients using perindopril arginine, even though similar
decreases in IOP were achieved with different therapies
in the two groups, may derive from the different effect
mechanisms of the two antihypertensive drugs.
The significant increase in CT in the perindopril
arginine group in this study, the first of its kind in the
literature, may be attributed to vasodilation emerging
in choroidal tissue, additional pharmacological effects
such as bradykinin accumulation, or drug idiosyncrasy.
However, long-term studies with larger numbers of
participants are now needed to clarify these causeand-effect relations. Another limitation of this study is
that factors such as smoking and sildenafil citrate and
caffeine use that might affect CT measurements were not
investigated. Long-term follow-up studies with greater
participation and investigation of all factors that might
impact CT may thus shed more light on these subjects.
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